Business Context and Reporting Period
This Form 8-K is filed by Graphite Bio, Inc. (not LENZ Therapeutics, Inc.) on May 12, 2022. The filing serves to announce the company's financial results and business progress for the first quarter ended March 31, 2022. The company is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Global Market under the symbol GRPH.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the input text.
Material Changes
The filing text does not provide specific data points to compare against the prior comparable period. It only indicates that a press release detailing the Q1 2022 results and business progress was issued on May 12, 2022.
Guidance, Outlook, and Risks
The filing references a press release titled "Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results." However, the text of this 8-K does not include specific management commentary, forward-looking guidance, risk factors, or details on contingencies. The document explicitly states that the information in the exhibit shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific Q1 2022 financial figures (revenue, net loss, cash position) in Exhibit 99.1 (the press release), as they are absent from this cover document.
- Confirm the company name is Graphite Bio, Inc. (GRPH), noting the discrepancy with the "LENZ Therapeutics" label in the request metadata.
- Review the "Recent Business Progress" section of the press release for updates on clinical trials or pipeline developments.
- Check for any updated cash runway estimates or financing activities mentioned in the full press release.